Long-term cost-effectiveness of CKD screening in middle-aged adults

Clicks: 2
ID: 333838
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #146 of 146 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 146 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Hypothesis Chronic kidney disease (CKD) is common in Finland and frequently remains undiagnosed until advanced stages. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) slow CKD progression and reduce cardio-renal events when used in addition to Renin-Angiotensin-Aldosterone System inhibitor (RAASi) treatment. We hypothesized that a one-time CKD screening program using measurements of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), followed by SGLT2i and RAASi treatment for identified CKD, would be cost-effective in Finland. Methods We developed a cohort-based Markov model to simulate lifetime CKD progression in a Finnish cohort aged 55 years under two strategies: (1) current practice (no screening) and (2) one-time screening with follow-up and SGLT2i and RAASi treatment for screen-positive CKD (eGFR <60 mL/min/1.73 m² and/or UACR ≥3 mg/mmol; confirmed on a repeat sample after ≥ 3 months to establish chronicity). All CKD stages (G1–G5, dialysis, transplant, and death) were included in the model, and screening could detect CKD at any stage, although the incremental detection was concentrated in earlier, previously undiagnosed stages (G1–G3). Outcomes included discounted costs, quality-adjusted life years (QALYs), life years, and clinical outcomes (acute kidney function decline, heart-failure hospital days, dialysis and transplant patient-years, and deaths). Results are reported as means with 95% confidence intervals (CI). Results Screening increased discounted lifetime costs per person by €907 (95% CI €334–2 553) and QALYs by 0.14 (95% CI 0.07–0.31), yielding an incremental cost-effectiveness ratio of €6 478/QALY. Screening increased life years by 0.30. Screening reduced acute kidney function decline (0.88 vs 0.90 events/person), heart-failure hospital days (6.47 vs 6.69 days/person), dialysis exposure (0.29 vs 0.32 patient-years/person) and transplant exposure (0.13 vs 0.14 patient-years/person). Conclusions In Finns aged 55 years, one-time CKD screening with eGFR/UACR followed by SGLT2i and RAASi treatment improves long-term outcomes and is likely cost-effective.
Reference Key
openalex_W7223467350 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kari Jalkanen, Lehtimäki Aku-Ville, Lavikainen Piia, Heiskanen Jari, Reijula Emmi, Kovalainen Piia, Satu Mäkelä, Marjamäki Tarja, Tuovinen Mikko, Janne Martikainen
Journal nephrology dialysis transplantation
Year 2026
DOI
10.1093/ndt/gfag252
URL
https://doi.org/10.1093/ndt/gfag252
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.